Matt Devalaraja

Biography

 He is a founder and leads the R&D efforts at Corvidia. Matt is an immunologist with over 16 years of experience in drug discovery and development across multiple therapeutic areas. Matt was Director of Emerging Innovations Unit at AstraZeneca, where he enabled multiple clinical studies and developed the core hypothesis of precision cardiovascular therapeutics that formed the basis for Corvidia. Prior to that he was Head of Immunology Research, Pharmacokinetics and Toxicology groups at Human Genome Sciences and was integral to the approval of Benlysta for Lupus and Raxibacumab for Anthrax. He started his career at Pfizer Ann Arbor and brought forth the first biologic program for Pfizer’s Global Immunology portfolio. As Head of Biologics Discovery at Pfizer Ann Arbor, he initiated multiple programs across various therapeutic areas including immunology and cardiovascular space, many of which are currently in late stages of clinical development. He is currently on the board of P2D Biosciences and is a founder of multiple startup biotech companies. Matt received his PhD from University of Kentucky and Post Doctoral training at Vanderbilt University.

Research Interest

 Immunology Research, Pharmacokinetics and Toxicology